US Patent

US12161640 — Opioid formulations

Method of Use · Assigned to Camurus AB · Expires 2032-07-26 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a depot formulation of buprenorphine, a controlled-release matrix with an organic solvent, for use in pain management and opioid maintenance.

USPTO Abstract

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4100 — Subutex
U-4100 — Subutex
U-4100 — Subutex
U-4100 — Subutex
U-4100 — Subutex
U-4100 — Subutex
U-4100 — Subutex

Patent Metadata

Patent number
US12161640
Jurisdiction
US
Classification
Method of Use
Expires
2032-07-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Camurus AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.